Biocon Biologics’ YESINTEK Receives USFDA Approval

On December 01, 2024, Biocon Biologics, a subsidiary of Biocon Ltd, announced that its biosimilar YESINTEK (Ustekinumab-kfce) received USFDA approval for treating Crohn’s disease, psoriasis, and psoriatic arthritis.

FDA Approval and Product Overview

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced that the U.S. Food and Drug Administration (FDA) has approved YESINTEK (Ustekinumab-kfce), a biosimilar to Janssen’s Stelara (Ustekinumab).

YESINTEK is a monoclonal antibody approved for the treatment of multiple conditions, including Crohn’s disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis.

In February 2024, Biocon Biologics informed the stock exchange that it had reached a settlement and licensing agreement with Janssen Biotech, Janssen Sciences Ireland, and Johnson & Johnson. This agreement allows for the commercialisation of YESINTEK in the U.S. by February 2025, contingent

Biocon Share Price Performance

On December 02, 2024, Biocon share price was trading 3.13% higher at ₹376.20 at 12:15 PM on the NSE. The stock opened at ₹375.05 higher than its previous close of ₹364.80.

About Biocon Biologics Ltd

Biocon Biologics, a subsidiary of Biocon Ltd, is a fully integrated global biosimilars company. It focuses on the development, manufacturing, and commercialization of biosimilars and biologic medicines. The company specializes in producing high-quality, affordable biosimilars across multiple therapeutic areas, including oncology, immunology, and ophthalmology.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.